SCHEMBL3565690

SCHEMBL3565690

Cc1cc(-c2ccc(C(F)(F)F)cc2)cc(-c2ccnc(Cl)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.53
S1PR3 Q99500 1/20 0.53
KIF11 P52732 1/20 0.42
CNR1 P21554 2/20 0.40
PSEN1 P49768 5/20 0.39
PSEN2 P49810 5/20 0.39
APH1B Q8WW43 5/20 0.39
NCSTN Q92542 5/20 0.39
APH1A Q96BI3 5/20 0.39
PSENEN Q9NZ42 5/20 0.39
CYP2D6 P10635 4/20 0.39
TOP1 P11387 2/20 0.39
SYK P43405 1/20 0.38
IDO1 P14902 1/20 0.38
CCNA2 P20248 2/20 0.36
CDK2 P24941 2/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
PIM1 P11309 1/20 0.36
CDK4 P11802 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3556332 0.84 S1PR1 (0.56) S1PR1S1PR3KIF11CNR1TOP1
SCHEMBL3559671 0.84 S1PR1 (0.55) S1PR1S1PR3KIF11CNR1TOP1
SCHEMBL3560497 0.82 S1PR1 (0.59) S1PR1S1PR3KIF11CNR1TOP1
SCHEMBL3563087 0.82 IDO1 (0.39) S1PR1S1PR3KIF11PSEN1PSEN2
SCHEMBL3563339 0.81 KIF11 (0.46) S1PR1S1PR3KIF11
SCHEMBL3285394 0.81 S1PR1 (0.64) S1PR1S1PR3KIF11CNR1IDO1
SCHEMBL3565887 0.81 S1PR1 (0.50) S1PR1S1PR3KIF11CNR1TOP1
SCHEMBL3572125 0.80 CCNT1 (0.45) KIF11PSEN1PSEN2APH1BNCSTN
SCHEMBL3570446 0.80 KIF11 (0.51) KIF11TOP1
SCHEMBL3565278 0.80 GRM2 (0.46) S1PR1S1PR3PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 S1PR1 1042/4885S1PR3 1066/4885KIF11 3845/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 S1PR1 306/4885S1PR3 276/4885KIF11 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.